Category Archives: Biochemistry

Global Automated Biochemistry Analyzers Market Growth, Top Major Manufacture, and Overview Forecast 2020-2025 – The Courier

The report titled Global Automated Biochemistry Analyzers Market 2020 by Manufacturers, Type and Application, Forecast to 2025 is a far-reaching review of the market size and trends with values. The report is a comprehensive study on global market analysis and insights. The report is a compilation of detailed market overview based on the idea of sorts, application, trends and opportunities, mergers and acquisitions, drivers and restraints, and a world reaching. The report focuses on the emerging trends in the global and regional spaces on all the significant components, such as market capacity, cost, price, demand and supply, production, profit, and competitive landscape. It offers a board interpretation of the global Automated Biochemistry Analyzers industry from a range of information that is collected through reputable and verified sources.

NOTE: Our analysts monitoring the situation across the globe explains that the market will generate remunerative prospects for producers post COVID-19 crisis. The report aims to provide an additional illustration of the latest scenario, economic slowdown, and COVID-19 impact on the overall industry.

Market Rundown:

The report analyzes past trends and future prospects in this report which makes it highly comprehensible for the analysis of the market. The report gives details of the market by definitions, applications, market outline, product determinations, and cost structures. The study additionally demonstrates the market rivalry scene and a relating point by point investigation of the significant merchant/producers in the global Automated Biochemistry Analyzers market. Then it presents a new undertaking SWOT investigation, venture probability, and examination. The report offers a forecast estimation of the valuation of the market 2020-2025.

DOWNLOAD FREE SAMPLE REPORT: https://www.marketsandresearch.biz/sample-request/63509

The report discusses a whole outlook on the challenges existing among the business along with the rising threats, constraints, and limitations. The report contains a full breakdown of the market dynamics like drivers, growth prospects, product portfolio, technological advancements, and a full analysis of the key competitors of the market. The worldwide Automated Biochemistry Analyzers market is any segmental into types, applications, technology, end-users, business verticals, and key geographies.

The key players studied in the report include: Abbott, Roche, Danaher, Hitachi, Thermo Fisher Scientific, Siemens

The most important types of global market products covered in this report are: Stationary Biochemistry Analyzers, Portable Biochemistry Analyzers

The most widely used downstream fields of the global market covered in this report are: Hospital and Diagnostic Laboratories, Home Care, and Academic, Research Institutes

Key regions and countries are covered in the global Automated Biochemistry Analyzers market as follows: North America (United States, Canada and Mexico), Europe (Germany, France, United Kingdom, Russia and Italy), Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia), South America (Brazil, Argentina), Middle East & Africa (Saudi Arabia, UAE, Egypt and South Africa)

The report consists of a generalized market study and overall details regarding the business opportunities to key stakeholders to expand their business and capture revenues. The global Automated Biochemistry Analyzers market report offers detailed analysis supported by reliable statistics on sale and revenue by players for the period 2015-2020. Other details included are company description, major business, product introduction, recent developments, sales by region, type, application, and by sales channel.

ACCESS FULL REPORT: https://www.marketsandresearch.biz/report/63509/global-automated-biochemistry-analyzers-market-2020-by-manufacturers-type-and-application-forecast-to-2025

Advance Information On The Market:

Customization of the Report:

This report can be customized to meet the clients requirements. Please connect with our sales team (sales@marketsandresearch.biz), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +1-201-465-4211 to share your research requirements.

Contact UsMark StoneHead of Business DevelopmentPhone: +1-201-465-4211Email: sales@marketsandresearch.bizWeb: http://www.marketsandresearch.biz

View post:
Global Automated Biochemistry Analyzers Market Growth, Top Major Manufacture, and Overview Forecast 2020-2025 - The Courier

Difficult Decisions 101: Balancing hands-on learning and safety – University of Michigan News

While new University of Michigan COVID guidelines are requiring most undergraduates to study from their homes for the winter semester, some classesclasses that are nearly impossible to conduct onlinewill continue to be taught in person.

Biochemistry 352 is one such class. Theres something essential about being in a lab to learn this kind of science, says U-M researcher Neil Marsh.

Srijoni Majhi.

Its the difference between driving a car and reading a book about driving a car. We think of lab experience as being mission-critical to teaching the undergraduates, said Marsh, professor of chemistry in the College of Literature, Science, and the Arts and professor of biological chemistry at Michigan Medicine. We did run remote labs but its a very, very poor substitution for a real lab.

Chemistry, he says, more than other types of science, relies on hands-on learning in the lab. Students in his Biochemistry 352 class learn basic biochemical techniques critical to performing experiments in chemistry. Seemingly straightforward skills such as using pipettes can be more complex when students use the instruments in person.

Of course, the ability to teach students these techniques was upended as the university attempted to deal with the coronavirus pandemic. During the fall semester, just 20% of class credit hours were offered in person.

The chemistry department revamped classes to ensure they met safety protocols. Marshs course includes about 100 students and typically involves a lecture and four sections of labs. Now, Marsh records 15-20 minute videos on certain topics that the students then watch before they attend their lab.

Typically, each of the four lab sections would meet once a week, with 16 students and one graduate student instructor leading the section. Now, only six people are allowed in a labfive students and a graduate instructorat a time. For all of the 100 students in the class to attend lab, extra sections had to be added and students attended lab every other week.

Balancing the desire to offer students hands-on experience and the safety of both graduate instructors and students has been a delicate process. The chemistry department offered students and graduate instructors the choice to attend or teach in person. Students uncomfortable with attending class in person could choose classes that were entirely virtual, and their ability to graduate was not compromised if they did not choose to take an otherwise required lab. The department likewise honored graduate instructors wishes to teach in person or virtually.

A survey was given to graduate student instructors to get their preferences as to whether or not they were willing to teach in person, and the only people that saw the results were the departments associate chair and one staff member, said Robert Kennedy, chair of the Department of Chemistry. The bigger point is that nobody was, or will be in winter, assigned to an in-person section if they do not want to teach an in-person section.

If no instructor wants to teach an in-person lab during the winter, Kennedy says, the department will hold no in-person labs.

In September, the Graduate Employees Organization called a strike to address health and safety concerns for GEO members working on campus. The group called for increased COVID testing, among other considerations. The organization ended its strike Sept. 16, accepting a stronger process to address these concerns. Now, for the winter semester, U-M will pare down the number of students on campus, reducing density in undergraduate residence halls and including increases in asymptomatic testing to detect virus infection.

Srijoni Majhi is one of the graduate students who volunteered to teach a lab section during the fall semester. She says she initially felt hesitant because she didnt want to spread the virus to her labmates and roommates.

Its not me alone. I have a roommate, and then I have my other labmates, Majhi said. If Im exposed, then its certain that the other people will be suffering because of me. But I talked to my labmates and they were very supportive.

Ironically, students may be safest in the biochemistry lab, says Marsh. Lab coats, glovesand goggles have long been required wear, and students, as everywhere on campus, are required to wear masks. Graduate student instructors also disinfect the labs after every class.

Theres also very good ventilation in the lab, Marsh said. In some ways, theyre actually much safer doing our lab course than they are pretty much anywhere else on campus, in terms of risk of exposure to the virus.

Its the ability to teach experiments that Majhi found most necessary in having an in-person labespecially this course, which is a new class. Students are familiar with general chemistry, and some students have already worked in research biology or biochemistry labs in other parts of the university. But for other students, this class is their introduction to the subject.

This is a 300-level course, so the students come very prepared to lab, but there are still students who we still have to help, she said. We have to keep in mind this is a very new biochemistry lab, so many of them are not aware of how to use pipettes or work with enzymes, or other simple techniques.

Jack Toor is an undergraduate who opted to take the in-person lab. A biochemistry major, Toor has done research in the U-M School of Dentistry. The first hands-on experience to surprise him? Pipetting.

We did this experiment in the beginning of our lab which seemed on the surface very lame. It was just learning how to use pipettes, said Toor, who plans to apply to medical school. I have been using those in my dental lab for a very long time, but I had never thought about how accurate they are, even after calibration.

The simple experiment involved asking the students to pipette ever-smaller amounts of waterdown to 20 microliters.

Ive never realized, once you get down to such low volumes, it actually is quite inaccurate, he said.

Another experiment the undergraduates performed was to identify proteins based on their molecular weights. The students put proteins in an acrylamide gel and ran an electric current through the gel. This arranges the proteins in proportion to their mass. Toor said to conduct this experiment himself was more valuable than being given the parameters of the experiment in an online format. After all, experiments shown in a video typically dont contain a blooper reel.

When I took my gel out of its casing, it ripped, and thats something your textbook never talks about, Toor said. I talked to Srijoni about it, who told me after I stained it, I would still be able to piece it back together. Its little things like that that your textbook wouldnt mention.

The changes the chemistry department has had to implement to meet safety requirements do have their silver linings, Marsh says. Although students are in the lab less frequently, the time they spend there might be higher quality. The student-to-teacher ratio is lower, and instead of having to share lab equipment to perform experiments with a partner or group, each student has his or her own equipment.

Now theres a much better teacher-to-student ratio in the lab, and students can really get the attention and help they need. Even though theyre only coming in every other week, we now have enough equipment that every student can do the experiment themselves, Marsh said. Weve also really prioritized the fact that were going to use that whole four-hour period. What weve seen is that the students have come to lab very focused. They really get down and do the work.

See the original post here:
Difficult Decisions 101: Balancing hands-on learning and safety - University of Michigan News

WPI Professor Elected a Fellow of the American Association for the Advancement of Science – WPI News

Suzanne Scarlata, Richard Whitcomb Professor of Chemistry and Biochemistry at Worcester Polytechnic Institute (WPI), has been elected a fellow of the American Association for the Advancement of Science (AAAS), the world's largest general scientific society.

Election as a fellow, an honor bestowed upon AAAS members by their peers since 1874, recognizes scientifically or socially distinguished efforts to advance science or its applications. Scarlata, along with this year's 488 other new fellows, will be recognized in the AAAS News & Notes section of the Nov. 27 issue of Science. She is being honored for her leadership in the biophysics community and for developing fluorescence methods to probe the dynamics of signaling proteins in vivo and in vitro.

Scarlata, who joined the university faculty in 2016, studies how small molecules in the bloodstream can change the behavior of cells. In particular, she is interested in how certain hormones and neurotransmitters can activate a family of organic molecules known as G proteins (guanine nucleotide-binding proteins), which are involved in transmitting signals from various stimuli from the exterior to the interior of cells.

G proteins help control how cells move, divide, and change structure; the signaling pathways they mediate are integral to a wide array of biological functions, including sensory perception, the regulation of the heart, nervous system, and reproduction, and the development of cancer. "Most current pharmaceuticals work through G proteins," Scarlata said.

Among her current research projects is a study of how G proteins can stimulate phospholipase C, an enzyme that raises the level of calcium in cells. This pathway is one of the main ways that allows cells to respond to many hormones and neurotransmitters to increase cellular calcium levels, which allows cells to move, divide, or die, depending on the specific circumstances, she told an interviewer for the Biophysical Society in 2016, the year she served as the societys president.

Since coming to WPI, Scarlata and her team have found a surprising new mechanism through which G proteins directly change the level and types of specific proteins in cells. This mechanism is very basic to almost all cell types and may underlie processes as diverse as changes in heart muscle with exercise and the formation of neurodegenerative plaques in the brain, she said.

Scarlata has received more than $10 million for her research from the National Institutes of Health, the American Heart Association, the Keck Foundation, the U.S. Department of Education, and other organizations. In addition, she has been the keynote speaker at several national and international meetings.

Before joining WPI, Scarlata was professor of physiology and biophysics at Stony Brook University, where she had taught since 1991. She previously served as assistant professor in the Department of Medicine at Cornell University Medical College and as a member of the technical staff at AT&T Bell Laboratories, where she developed optical testing methods for printed circuit boards. She received a BA in chemistry from Temple University and a PhD in physical chemistry from the University of Illinois, Urbana-Champaign.

She is associate editor of the Journal of Bioenergetics and Biomembranes and serves on the editorial boards of the Journal of Fluorescence and the Journal of Membrane Biology. She has also served on the editorial boards of Analytical Biochemistry, BBA Biomembranes, F1000, Journal of Biological Chemistry and Analytical Biochemistry, and Methods and Application of Fluorescence Spectroscopy. From 2001 to 2004, she was an American Heart Association Established Investigator. She was elected president of the Biophysical Society in 2015 and served during the 2016 calendar year.

The rest is here:
WPI Professor Elected a Fellow of the American Association for the Advancement of Science - WPI News

UO’s von Hippel receives Biophysical Society award | Around the O – AroundtheO

UO biophysical chemist Peter von Hippel has been recognized as the 2021 recipient of the Ignacio Tinoco Award from the Biophysical Society for his exceptional contributions to the field of biophysics.

An emeritus professor in the Department of Chemistry and Biochemistry and a member of the Institute of Molecular Biology, von Hippel has spent decades developing approaches to studying the molecular basis of gene expression and played a leading role in creating the major discipline of modern molecular biophysics.

The award really honors all the great people who have worked in my lab over the last 50 years and in many cases have subsequently gone on to having successful scientific careers of their own, von Hippel said.

Named after the late Ignacio Nacho Tinoco, a pioneering biophysicist, educator and mentor at the University of California, Berkeley, the Tinoco Award recognizes investigators in the field of biophysics who have made major scientific contributions, while also maintaining collaborative, inclusive and engaging environments.

Von Hippel has mentored, educated and inspired many students and colleagues over the years, say those who know him, such as Andy Marcus, a professor in the Department of Chemistry and Biochemistry. Marcus has worked with von Hippel in recent years to develop new approaches to studying the mechanisms and dynamics of the central biological processes of DNA transcription and replication.

Its really not possible to overstate the significance of Pete von Hippels scientific impact over the course of his 50-plus-year career, Marcus said. He is an accomplished leader in every sense of the word. In spite of his huge scientific stature, Pete is remarkably modest.To interact with him scientifically is an enriching experience because henaturallyworks to elevate everyone around him.

After finishing his doctorate at Massachusetts Institute of Technology in 1955, von Hippel became a researcher, as well as a commissioned officer in the U.S. Navy, at the Naval Medical Research Institute in Bethesda, Maryland. In 1959 he became an assistant, and then an associate, professor in the Department of Biochemistry at Dartmouth Medical School in Hanover, New Hampshire.

He moved to Oregon in 1967 to continue his National Institutes of Health- and National Science Foundationsupported research and teaching in the fields of biophysical chemistry and molecular biology. He was honored by election to the National Academy of Sciences in 1978, to the American Academy of Arts and Sciences in 1979 and to the American Philosophical Society in 2004. He was also appointed a Career American Cancer Society Research Professor in 1989.

Von Hippel uses physical biochemical approaches to study the molecular basis of gene expression. As Marcus describes it, von Hippel is largely responsible for writing the modern "rule book to understand the physical-chemical basis of how genetic macromolecules, like DNA and RNA, carry out their biological functions and is recognized by biochemists and biophysicists around the world for his pioneering work.

Bruce Blonigen, dean of the College of Arts and Sciences, pointed to the significant impact of von Hippels hundreds of published research papers and the numerous high-level research grants he has received over the years.

Even more extraordinary is the significance of the discoveries he has made and how it has advanced our knowledge of the molecular basis of gene expression, Blonigen said. Im thrilled that his career achievements have been recognized by this award.

Read more from the original source:
UO's von Hippel receives Biophysical Society award | Around the O - AroundtheO

The Biochemistry Analyser Market To Revive The Growth Indices, Reach US$ 4700 Million – Cheshire Media

Market Report Summary

For Full Information -> Click Here

Read Full Press Release Below

The clinical use of biochemistry analyzers in measurement solutions such as latex agglutination, ion-selective potentiometry, and colorimetric & photometric testing. In addition to this, accuracy of biochemistry analyzers in analyzing blood and urine samples has benefited pathology labs and diagnostic centers across the globe. Persistence Market Research predicts that the global demand for biochemistry analyzers will continue to soar on the grounds of such factors.

A recent report published by Persistence Market Research projects that by the end of 2024, the global market for biochemistry analyzers will reach US$ 4,625.3 Mn in terms of value.

Get Sample Copy of Report @ https://www.persistencemarketresearch.com/samples/6451

Company Profiles

Get To Know Methodology of Report @ https://www.persistencemarketresearch.com/methodology/6451

Key findings in the report cite that the use of chemistry analyzers spans from high-throughput clinical labs to point-of-care clinics, and its use for testing enzymes, electrolytes and proteins is gaining traction.

The report current values the globalbiochemistry analyzer marketat a little over US$ 3,000 Mn. During the forecast period, revenues generated through global sales of biochemistry analyzers are, thus, expected to soar at a steady CAGR of 5.5%.

Key Research Insights from the Report include:

The global market for biochemistry analyzers represents absolute $ opportunity of US$ 154.6 Mn in 2017 over 2016 and incremental opportunity of US$ 1,570.8 Mn between 2016 and 2024

Apart from clinical diagnostics, critical applications of biochemistry analyzers include drugs-of-abuse testing and diagnostic testing of patients metabolic functions

Access Full Report @ https://www.persistencemarketresearch.com/checkout/6451

Over 40% of biochemistry analyzers sold across the globe during the forecast period will be concentrated in North America

Demand for biochemistry analyzers is also expected to surge in Asia-Pacific, revenues from which will record steadfast growth at 6.1% CAGR

Leading manufacturers of biochemistry analyzers are developing multiplexing analyzers a cost-effective upgrade to existing product line

The report further reveals that fully-automated biochemistry analyzers will remain in great demand in the years to come. In 2017 and beyond, more than 85% of global biochemistry analyzer revenues will be accounted by sales of fully-automated biochemistry analyzers.

Moreover, clinical diagnostics will also remain the largest application of biochemistry analyzers throughout the forecast period. Revenues accounted by global sales of biochemistry analyzers in clinical diagnostics are anticipated to register speedy growth at 5.7% CAGR.

The report further identifies diagnostic centers as largest end-users of biochemistry analyzers in the world. On the other hand, rising number of point-of-care diagnostic labs instated in hospitals will render a key end-user of biochemistry analyzers. Together, hospitals and diagnostics centers will be responsible for procure over two-third of global biochemistry analyzers revenues through 2024.

Explore Extensive Coverage of PMR`sLife Sciences & Transformational HealthLandscape

Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance.

To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.

Our client success stories feature a range of clients from Fortune 500 companies to fast-growing startups. PMRs collaborative environment is committed to building industry-specific solutions by transforming data from multiple streams into a strategic asset.

Contact us:

Ashish KoltePersistence Market ResearchAddress 305 Broadway, 7th FloorNew York City,NY 10007 United StatesU.S. Ph. +1-646-568-7751USA-Canada Toll-free +1 800-961-0353Sales[emailprotected]Website https://www.persistencemarketresearch.com

View original post here:
The Biochemistry Analyser Market To Revive The Growth Indices, Reach US$ 4700 Million - Cheshire Media

Biochemistry Analyzer Market 2020 Global Industry Analysis, Trends and Forecast 2026 : Mevion, ProNova, ProTom International, IBA, Varian…

This extensive research report focusing on global Biochemistry Analyzer market portrays a detailed analytical assessment of notable trends, future specific market growth opportunities, end-user profile as well as challenge overview of the current Biochemistry Analyzer market scenario has also been encapsulated in the report. The primary focus of the report is to highlight and understand multiple market developments across the global Biochemistry Analyzer market ecosystem that influence logical reader discretion.This ready-to-refer market intelligence report on global Biochemistry Analyzer market entails a detailed analysis of the industrial ecosystem, followed by a highly reliable segment overview evaluated on multi-factor analysis, market size and dimensions in terms of volumetric gains and returns.

Get sample copy of Biochemistry Analyzer Market report @ https://www.orbispharmareports.com/sample-request/79842

Competitive Landscape Detailed Analysis:

* Followed by constant and thorough research initiatives in data unraveling process pertaining to global Biochemistry Analyzer market, stringent curation processes have been directed to understand growth prognosis and development spanning across regional hubs and their respective performance and evaluation in terms of various macro and micro elements that decide further growth prognosis in global Biochemistry Analyzer market.* The competitive analysis section of this report on global Biochemistry Analyzer market is dedicated to identifying and profiling various players in terms of their market positioning, product and service developments, technological investments as well as milestones achievement.* The report is aimed to enable seamless understanding and comprehension of the multi-faceted developments. Further in the report, readers are also offered substantial cues and hints on market strategies undertaken by various manufacturers operating across local and global realms.* An effortless deduction of the strategies aid market players to know the potential of these business tactics and tricks and their potential in steering high revenue growth and concomitant returns in global Biochemistry Analyzer market.Besides presenting a detailed synopsis of the current market scenario, this section of the report also includes versatile details on the overall ecosystem, key trends, market catalysts as well as threats and challenges that seem to significantly impact revenue generation in the Biochemistry Analyzer market.

Major Company Profiles operating in the Biochemistry Analyzer Market:

QIAGENAbbottBio-Rad LaboratoriesEMD Millipore CorporationSigma-AldrichAgilent TechnologiesGE HealthcareBeckman Coulter/DanaherTakara BioRocheThermo Fisher ScientificBD

Browse the complete report @ https://www.orbispharmareports.com/global-biochemistry-analyzer-market-report-2019-competitive-landscape-trends-and-opportunities/

Frequently Asked Questions:

* In terms of product and application based segmentation, which segment is likely to remain most promising?* Based on concurrent developments, which trends are likely to remain most dominant through the forecast span?* Considering the pandemic crisis and other associated alterations, what could be the most relevant market projections?* Who would continue to remain atop the growth curve in global Biochemistry Analyzer market through the forecast years?* What are the top threats and challenges identified in the Biochemistry Analyzer market?

By the product type, the market is primarily split into

Type 1Type 2Type 3

By the application, this report covers the following segments

ResearchMolecular BiotechnologyHuman ImmunologyGeneticsDiagnosisBiosciencesEducation

The report representing the global Biochemistry Analyzer market is an intensive research based documentation shedding enormous light on market developments, noteworthy trends as well a competitive vendor activities and performance analysis besides evaluating competition positioning that gradually direct hefty revenue flow and sustenance in global Biochemistry Analyzer market. The report also entails significant details on COVID-19 spread and their effective management.Further in the report reading, readers are expected to win cues on exclusive regional and country specific elements of the Biochemistry Analyzer market. Besides segregating the growth hotspots, this section embodies versatile understanding concerning various growth harnessing industrial practices as well as strategic aid favoring uncompromised growth and sustainable revenue returns in global Biochemistry Analyzer market.

For Any Query on the Biochemistry Analyzer Market: https://www.orbispharmareports.com/enquiry-before-buying/79842

About Us :

At Orbispharma we curate the most relevant news stories, features, analysis and research reports on the important challenges undertaken by the pharmaceutical and related sectors. Our editorial philosophy is to bring you sharp, focused and informed perspective of industries, the end users and application of all upcoming trends into the pharma sector. Orbispharma believes in conversations that can bring a change in one of the most crucial economic sectors in the world. With these conversations we wish our customers to make sound business decisions with right business intelligence.

Contact Us :

Follow this link:
Biochemistry Analyzer Market 2020 Global Industry Analysis, Trends and Forecast 2026 : Mevion, ProNova, ProTom International, IBA, Varian...

November: Biofriendly protocells | News and features – University of Bristol

An international team of researchers from Bristol and China has prepared biocompatible protocells that generate nitric oxide gas a known reagent for blood vessel dilation - that when placed inside blood vessels expand the biological tissue.

In a new study published today in Nature Chemistry, Professor Stephen Mann and Dr Mei Li from Bristols School of Chemistry, together with Associate Professor Jianbo Liu and colleagues at Hunan University and Central South University in China, prepared synthetic protocells coated in red blood cell fragments for use as nitric oxide generating bio-bots within blood vessels.

Coating the protocells led to increased levels of biocompatibility and longer blood circulation times. Critically, the team trapped an enzyme inside the protocells which, in the presence of glucose, produced hydrogen peroxide. This was then used by haemoglobin in the protocell membrane to degrade the drug molecule hydroxyurea into nitric oxide gas.

When placed inside small pieces of blood vessels, or injected into a carotid artery, the protocells produced sufficient amounts of nitric oxide to initiate the biochemical pathways responsible for blood vessel vasodilation.

Although at a very early stage of development, the new approach could have significant benefits in biomedicine, cellular diagnostics and bioengineering.

Professor Stephen Mann, Co-Director of the Max Planck Bristol Centre for Minimal Biology at Bristol, said: This work could open up a new horizon in protocell research because it highlights the opportunities for creating therapeutic, cell-like objects that can directly interface with living biological tissues.

Associate Professor Jianbo Liu at Hunan University added: We are all really excited about our proof-of-concept studies but there is a lot of work still to be done before protocells can be used effectively as bio-bots in therapeutic applications. But the potential looks enormous.

Enzyme-mediated nitric oxide production in vasoactive erythrocyte membrane-enclosed coacervate protocellsby Liu S, Zhang Y, Li M, Xiong L, Yang X, He X, Wang K, Liu J and Mann S. in Nature Chemistry.

Max Planck Bristol Centre for Minimal BiologyThe Max Planck-Bristol Centre for Minimal Biology, a partnership between the University of Bristol and the Max Planck Society for the Advancement of Science (MPG) in Germany, aims to advance the future of health and medicine by understanding the fundamental nature of life.

Minimal biology is a new emerging field at the interface between the physical and life sciences. It aims to design and build artificial cells, minimal genomes, virus-like nanodevices and new cellular scaffolds, and seeks to understand the foundations of life and how it arose from non-living matter.

Led by Bristol ProfessorsImre Berger(Biochemistry),Stephen Mann(Chemistry) andDek Woolfson(Chemistry and Biochemistry), and ProfessorsJoachim Spatz(Heidelberg),Tanja Weil(Mainz) andPetra Schwille(Munich) at Max Planck Institutes in Germany, the Centre is based in theSchool of Chemistryat the University of Bristol. A paramount objective is to train early career scientists in minimal biology and biodesign.

What is Minimal Biology?Minimal biology is an emerging research field at the interface between the physical and life sciences. It applies principles and methods from the former to construct new systems that mimic or augment living cells and organs.

About Bristol BioDesign InstituteBristol BioDesign Institute(BBI) is the University of Bristol's Specialist Research Institute for synthetic biology. With wide-ranging applications from health to food security, BBI combines pioneering synthetic biology approaches with understanding biomolecular systems to deliver the rational design and engineering of biological systems for useful purposes.

This is delivered through multidisciplinary research which brings together postgraduate and postdoctoral researchers, academics, policy makers and industry, whilst also engaging the public with emerging solutions to global challenges.

Read the original here:
November: Biofriendly protocells | News and features - University of Bristol

Mibelle Biochemistry announces: Mibelle Biochemistrys Ability to Introduce Breakthrough Active Ingredients for the Personal Care Market by Frost and…

18-Nov-2020

Ingredients | Marketing

The company's active ingredient product lines meet consumer expectations of quality, performance andsustainability

Based on its recent analysis of the global personal care active ingredients market, Frost & Sullivan recognises Mibelle AG Biochemistry with the 2020 Global Company of the Year Award.

It has successfully introduced several breakthrough sustainable active ingredients, whose efficacy is supported by in-vivo and in-vitro study results. Mibelle Biochemistry is a pioneer with regards to using senolytics to delay skin aging in cosmetic applications, which has helped the company achieve a leading positioning in the market.

"Demonstrating its expertise in recognising the dynamic needs of the cosmetics industry, Mibelle Biochemistry launched the Alpine Rose Active ingredient to fight skin aging," said Prateeksha Kaul Research Analyst.

"This ingredient contains a natural senolytic agent extracted from the Alpine rose leaves in the Swiss Alps to eliminate senescent cells, which are the cells responsible for ageing, without affecting the neighboring cells.

"This halts the skins aging process while rejuvenating it and increasing its elasticity. This active also meets the rising demand fornatural and sustainable products over harsh chemicals that are harmful to both the environment and the skin."

Similarly, in response to the growing interest in phytocannabinods, Mibelle Biochemistry introduced an encapsulated cannabidiol (CBD) ingredient, the Lipobelle Pino C. Other players in the market have had limited success with CBD in spite of its potential benefits for the skin because it is not soluble in water.

Mibelle addressed this limitation with the Lipobelle Pino C. By encapsulating the CBD into a nanoemulsion using hemp oil, Mibelle made it water-soluble and stable in cosmetic formulations.

Its combination with an extract from Swiss stone pines also helps the product fight inflammation. Lipobelle Pino C exploits the anti-inflammatory and regenerating effects of CBD for cosmetic benefits such as easing facial tension, reducing inflammation, and regenerating tissue.

Mibelle Biochemistry has been a pioneer in utilising interesting biochemical concepts for its active ingredients. In 2008, it gained a first-mover advantage with the launch of its active ingredient PhytoCellTec Malus Domestica, which involved the application of stem cells in cosmetics for the very first time.

In 2019, Mibelle utilised its PhytoCellTec technology to launch the PhytoCellTec Goji, which stimulates the mesenchymal stem cell (MSC) culture with goji stem cells for enhancing face shape by preventing the skin from sagging. The success of this technology and other recent innovations has allowed the company to achieve a 15 percent growth rate annually.

Each year, Frost & Sullivan presents a Company of the Year award to the organisation that demonstrates excellence in terms of growth strategy and implementation in its field.

The award recognises a high degree of innovation with products and technologies, and the resulting leadership in terms of customer value and marketpenetration.

Frost & Sullivan Best Practices awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development.

Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research to identify best practices in the industry.

The rest is here:
Mibelle Biochemistry announces: Mibelle Biochemistrys Ability to Introduce Breakthrough Active Ingredients for the Personal Care Market by Frost and...

Mibelle Biochemistry’s Ability to Introduce Breakthrough Active Ingredients for the Personal Care Market Lauded by Frost & Sullivan – PR Newswire…

The company's active ingredient product lines meet consumer expectations of quality, performance, and sustainability

LONDON, Nov. 18, 2020 /PRNewswire/ --Based on its recent analysis of the global personal care active ingredientsmarket, Frost & Sullivan recognizes Mibelle AG Biochemistry with the 2020 Global Company of the Year Award. It has successfully introduced several breakthrough sustainable active ingredients, whose efficacy is shttps://mma.prnewswire.com/media/1337466/Mibelle_Award.jpg upported by in-vivo and in-vitro study results. Mibelle is a pioneer with regards to using senolytics to delay skin aging in cosmetic applications, which has helped the company achieve a leading positioning in the market.

Photo - https://mma.prnewswire.com/media/1337466/Mibelle_Award.jpg

Click here to view the full multimedia release: https://best-practices.frost.com/mibelle-biochemistry/

"Demonstrating its expertise in recognizing the dynamic needs of the cosmetics industry, Mibelle launched the Alpine Rose Active line of products to fight skin aging,"said Prateeksha Kaul Research Analyst. "This line of products uses a natural senolytic agent extracted from the Alpine rose leaves in the Swiss Alps to eliminate senescent cells, which are the cells responsible for aging, without affecting the neighboring cells. This halts the skin's aging process while rejuvenating it and increasing its elasticity. This product also meets the rising demand for natural and sustainable products over harsh chemicals that are harmful to both the environment and the skin."

Similarly, in response to the growing interest in phytocannabinods, Mibelle introduced an encapsulated cannabidiol (CBD) product, the Lipobelle Pino C. Other players in the market have had limited success with CBD in spite of its potential benefits for the skin because it is not soluble in water. Mibelle addressed this limitation with the Lipobelle Pino C. By encapsulating the CBD into a nanoemulsion using hemp oil, Mibelle made it water-soluble and stable in cosmetic formulations. Its combination with an extract from Swiss stone pines also helps the product fight inflammation. Lipobelle Pino C exploits the anti-inflammatory and regenerating effects of CBD for cosmetic benefits such as easing facial tension, reducing inflammation, and regenerating tissue.

Mibelle has been a pioneer in utilizing interesting biochemical concepts for its active ingredients. In 2008, it gained a first-mover advantage with the launch of its active ingredient PhytoCellTec Malus Domestica, which involved the application of stem cells in cosmetics for the very first time. In 2019, Mibelle utilized its PhytoCellTec technology to launch the PhytoCellTec Goji, which stimulates the mesenchymal stem cell (MSC) culture with goji stem cells for enhancing face shape by preventing the skin from sagging. The success of this technology and other recent innovations has allowed the company to achieve a 15 percent growth rate annually.

"Mibelle works closely with certification bodies to analyze the ingredients, raw materials, and processes to obtain the required certifications for its products. It also collaborates with personal care product manufacturers to offer premium high-quality products that benefit the end user," noted Kaul. "With its ability to introduce breakthrough active ingredients, Mibelle AG Biochemistry has carved a niche for itself in the personal care industry. It has consistently adopted a holistic innovation approach that has enabled it to consistently develop novel concepts and ingredients."

Each year, Frost & Sullivan presents a Company of the Year award to the organization that demonstrates excellence in terms of growth strategy and implementation in its field. The award recognizes a high degree of innovation with products and technologies, and the resulting leadership in terms of customer value and market penetration.

Frost & Sullivan Best Practices awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research to identify best practices in the industry.

About Frost & Sullivan

For over five decades, Frost & Sullivan has become world-renowned for its role in helping investors, corporate leaders, and governments navigate economic changes and identify disruptive technologies, Mega Trends, new business models, and companies to action, resulting in a continuous flow of growth opportunities to drive future success. Contact us: Start the discussion.

Contact:

Harley GadomskiP: 12104778469E: [emailprotected]

About Mibelle AG Biochemistry

Mibelle Biochemistry designs and develops innovative, high-quality actives based on naturally derived compounds and profound scientific know-how. Inspired by nature - Realized by Science.

For more information on Mibelle Biochemistry, please visit http://www.mibellebiochemistry.com

Contact:

Esther Belser Mibelle Biochemistry, SwitzerlandHead of MarketingPhone: +41 62 836 13 47Email: [emailprotected]

http://www.frost.com

SOURCE Frost & Sullivan

Originally posted here:
Mibelle Biochemistry's Ability to Introduce Breakthrough Active Ingredients for the Personal Care Market Lauded by Frost & Sullivan - PR Newswire...

NeuBase Therapeutics Announces Addition of Eriks Rozners, Ph.D. and Randy Davis, MBA to Scientific Advisory Board – BioSpace

PITTSBURGH, Nov. 17, 2020 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) ("NeuBase" or the "Company"), a biotechnology company accelerating the genetic revolution using a new class of synthetic medicines, today announced the addition of Eriks Rozners, Ph.D. and Randy Davis, MBA to its scientific advisory board (SAB). Dr. Rozners, an expert in nucleic acid biochemistry, and Mr. Davis, a biotechnology industry veteran, bring extensive experience to NeuBase.

"We are thrilled to welcome Eriks and Randy to the NeuBase scientific advisory board. Their unique perspectives gained over their distinctive careers will undoubtedly provide valuable insight and complement our team of renowned experts," said Dietrich A. Stephan, Ph.D., chief executive officer of NeuBase. "We believe that our platform, which relies on elegant peptide nucleic acid chemistry, is first in class and has the potential to change the treatment landscape for a range of genetic conditions, both common and rare. We are honored that Eriks, a leading expert in developing technologies which scan duplex genomic targets without invasion via triplex binding so as to co-localize pharmacophores with their targets, recognizes this, and we are eager to leverage his unparalleled knowledge as we optimize our PATrOL platform. Additionally, Randys extensive experience in semiconductor-based single molecule nucleic acid sequencing perfectly complements the strengths of each member of our SAB and brings atomic-scale measurement capabilities to the company. We look forward to benefiting from his vast knowledge as we continue to advance our PATrOL-enabled therapies under the guidance of our outstanding group of scientific advisors."

Dr. Eriks Rozners is a leading expert in the chemistry and biochemistry of nucleic acids and brings his expertise to NeuBase as the Company is optimizing and developing its PATrOL platform. He is a professor and the chairman of the Department of Chemistry at Binghamton University, where his lab focuses on the use of organic chemistry to develop unique model systems and tools for the studies and practical applications of nucleic acid biochemistry. Dr. Rozners received a bachelor's degree in chemical engineering and a doctorate in organic chemistry from Riga Technical University.

Mr. Randy Davis is a seasoned industry veteran with expertise in the field of biotechnology and was one of the founding members of Genia Technologies, a company developing a next-generation sequencing platform, which was acquired by Roche in 2014. In addition, he has served as a member or investor in half a dozen biotech companies and has authored or co-authored over 20 patent applications. Mr. Davis graduated from Tokyo Electrical University with a degree in electrical engineering and went on to receive an MBA from San Jose State University. In 2002, he continued his education at California State University East Bay, where he received a bachelor's and master's degree in molecular biology before moving on to various industry roles.

About NeuBase Therapeutics, Inc.NeuBase is accelerating the genetic revolution using a new class of synthetic medicines. NeuBases designer PATrOL therapies are centered around its proprietary drug scaffold to address genetic diseases at the source by combining the highly targeted approach of traditional genetic therapies with the broad organ distribution capabilities of small molecules. With an initial focus on silencing disease-causing mutations in debilitating neurological, neuromuscular and oncologic disorders, NeuBase is committed to redefining medicine for the millions of patients with both common and rare conditions. To learn more, visit http://www.neubasetherapeutics.com.

Use of Forward-Looking StatementsThis press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act. These forward-looking statements are distinguished by use of words such as "will," "would," "anticipate," "expect," "believe," "designed," "plan," or "intend," the negative of these terms, and similar references to future periods. These views involve risks and uncertainties that are difficult to predict and, accordingly, our actual results may differ materially from the results discussed in our forward-looking statements. Our forward-looking statements contained herein speak only as of the date of this press release. Factors or events that we cannot predict, including those risk factors contained in our filings with the U.S. Securities and Exchange Commission, may cause our actual results to differ from those expressed in forward-looking statements. The Company may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements, and you should not place undue reliance on these forward-looking statements. Because such statements deal with future events and are based on the Company's current expectations, they are subject to various risks and uncertainties, and actual results, performance or achievements of the Company could differ materially from those described in or implied by the statements in this press release, including: the Company's plans to develop and commercialize its product candidates; the timing of initiation of the Company's planned clinical trials; the timing of the availability of data from the Company's clinical trials; the timing of any planned investigational new drug application or new drug application; the Company's plans to research, develop and commercialize its current and future product candidates; the clinical utility, potential benefits and market acceptance of the Company's product candidates; the Company's commercialization, marketing and manufacturing capabilities and strategy; global health conditions, including the impact of COVID-19; the Company's ability to protect its intellectual property position; and the requirement for additional capital to continue to advance these product candidates, which may not be available on favorable terms or at all, as well as those risk factors contained in our filings with the U.S. Securities and Exchange Commission. Except as otherwise required by law, the Company disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date hereof, whether as a result of new information, future events or circumstances or otherwise.

NeuBase Investor Contact:Dan FerryManaging DirectorLifeSci Advisors, LLCdaniel@lifesciadvisors.comOP: (617) 430-7576

NeuBase Media Contact:Cait Williamson, Ph.D.LifeSci Communicationscait@lifescicomms.comOP: (646) 751-4366

See the rest here:
NeuBase Therapeutics Announces Addition of Eriks Rozners, Ph.D. and Randy Davis, MBA to Scientific Advisory Board - BioSpace